The evaluation of claudin-18 (CLDN18) by immunohistochemistry (IHC) has already entered routine diagnostic activity as a predictive biomarker for patients with gastric and gastroesophageal junction adenocarcinomas. This evidence concerns the gene CLDN18 and gastroesophageal junction adenocarcinoma.